JPRN-UMIN000008970已完成未知
Randomized phase II trial comparing carboplatin plus irinotecan with carboplatin plus amrubicine for extensive disease small-cell lung cancer - Randomized phase II of CBDCA+CPT vs CBDCA+AMR for ED-SCLC
orth-Japan lung cancer group0 个研究点目标入组 70 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe co-morbidities 2. Symptomatic brain metastasis 3. Not appropriate for clinical trial decided by the attending physician
研究者
相似试验
进行中（未招募）
不适用
A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer.Ensayo piloto randomizado en fase II que compara carboplatino y docetaxel en pacientes con cáncer de mama genético metastásico. - BRCA TrialEUCTR2004-001496-20-ESniversity College London
进行中（未招募）
不适用
Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer.endometrial cancerMedDRA version: 14.1Level: LLTClassification code 10014770Term: Endometrioid adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003301-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI108
进行中（未招募）
1 期
A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancerPlatinum-sensitive recurrent ovarian cancerMedDRA version: 19.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2010-018849-59-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
进行中（未招募）
1 期
A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination .Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.MedDRA version: 20.0Level: LLTClassification code 10006888Term: Ca ovarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002860-42-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE234
进行中（未招募）
不适用
A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer. - PLANETMetastatic Breast CancerEUCTR2010-018837-23-GBCardiff University